ArticleInfection2026
Plasma-derived extracellular vesicle microRNA as a potential biomarker associated with disease progression in non-severe dengue infection.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDengue can manifest as a mild febrile illness to life-threatening haemorrhagic fever. The early identification of patients at risk of disease progression remains challenging, particularly in non-severe cases. Therefore, this study aims to investigate the capability of extracellular vesicle plasma microRNA (miRNA) expression as a biomarker in dengue infection. METHODOLOGY: A total of 52 dengue patients (26 dengue with warning signs and 26 dengue without warning signs) were enrolled. Microarray analysis was utilised to profile miRNA derived from plasma extracellular vesicles to identify potential biomarkers associated with disease progression. Target genes were predicted bioinformatically to construct a miRNA-mRNA interaction network and identify key hub genes. The expression levels of miRNAs were validated through quantitative reverse-transcription polymerase chain reaction (RT-qPCR), and their diagnostic efficacy was evaluated using receiver operating characteristic (ROC) curve analysis. Additional functional enrichment analysis, gene ontology, and co-expression studies were conducted. An in vitro experiment using THP-1 cells investigated how hsa-miR-107 regulates P2RY12 expression, with further validation of P2RY12 levels through RT-qPCR using GAPDH as a reference.
resultsMicroarray profiling identified 24 upregulated miRNAs in dengue patients with warning signs, notably hsa-miR-107 and hsa-miR-6879-5p, which were selected as potential biomarkers. Correlation analysis revealed that platelet count exhibited a statistically significant, moderate positive correlation with the hsa-miR-107 expression value. ROC analysis demonstrated strong diagnostic performance, linking these miRNAs to the platelet dysfunction and altered vascular permeability associated with disease severity. Furthermore, functional analysis supported the involvement of these pathways in dengue pathogenesis, and in vitro transfection confirmed that hsa-miR-107 actively decreases P2RY12 expression.
conclusionThis study highlights the expression of hsa-miR-107 and hsa-miR-6879-5p as candidate biomarkers associated with clinical warning signs in dengue infection. These findings could pave the way for improved diagnostic and monitoring strategies.
Indexed as
Identifiers
42627622What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.